Lynparza Archives -

Merck & Co’s two powerhouse oncology drugs – Keytruda and Lynparza – have failed to show efficacy when

Merck trial of Keytruda, Lynparza combo in prostate cancer fails

https://pharmaphorum.com/news/merck-trial-of-keytruda-lynparza-combo-in-prostate-cancer-fail/

Market Access/ News/ News

After a Scottish aye, NICE says no to Lynparza for prostate cancer

Phil Taylor AstraZeneca, HEOR, Lynparza, NICE, PARP inhibitor, Prostate cancer 0 Comment

AstraZeneca’s PARP inhibitor Lynparza should not be made available routinely on the NHS n England and Wales as

After a Scottish aye, NICE says no to Lynparza for prostate cancer

https://pharmaphorum.com/news/after-a-scottish-aye-nice-says-no-to-lynparza-for-prostate-cancer/

News/ News/ Oncology

AZ eyes FDA verdict on Lynparza in adjuvant breast cancer in Q1

Phil Taylor adjuvant, AstraZeneca, breast cancer, Lynparza, Merck & Co, Oncology, Targeted Therapies 0 Comment

The FDA will deliver a verdict on AstraZeneca’s PARP inhibitor Lynparza as an adjuvant treatment for breast cancer

AZ eyes FDA verdict on Lynparza in adjuvant breast cancer in Q1

https://pharmaphorum.com/news/az-eyes-fda-verdict-on-lynparza-in-adjuvant-breast-cancer-in-q1/

News/ News/ Oncology

PROpel study backs Lynparza combo in first-line prostate cancer

Phil Taylor AstraZeneca, Lynparza, Merck & Co, Oncology, PARP inhibitor, Prostate cancer 0 Comment

AstraZeneca and Merck & Co PARP inhibitor Lynparza is already used to treat prostate cancer associated with a

PROpel study backs Lynparza combo in first-line prostate cancer

https://pharmaphorum.com/news/propel-study-backs-lynparza-combo-in-first-line-prostate-cancer/

News/ News/ Sales and Marketing

AZ’s COVID-19 jab sales top $1.2bn, but come at a loss

Phil Taylor AstraZeneca, coronavirus, COVID-19, COVID-19 vaccine, Farxiga, Financial, Imfinzi, Lynparza, Tagrisso 0 Comment

AstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in

AZ’s COVID-19 jab sales top $1.2bn, but come at a loss

https://pharmaphorum.com/news/azs-covid-19-jab-sales-top-1-2bn-but-come-at-a-loss/

News/ News/ Oncology

ASCO21: Lynparza aces adjuvant breast cancer therapy trial

Phil Taylor adjuvant, ASCO 2021, AstraZeneca, breast cancer, Lynparza, Merck & Co, Oncology, PARP inhibitor 0 Comment

AstraZeneca and Merck & Co’s Lynparza is primed for even wider use in the treatment of breast cancer

ASCO21: Lynparza aces adjuvant breast cancer therapy trial

https://pharmaphorum.com/news/asco21-lynparza-aces-adjuvant-breast-cancer-therapy-trial/

Market Access/ News/ News

NICE says no to AZ’s Lynparza for prostate cancer

Phil Taylor AstraZeneca, HEOR, Lynparza, NHS, NICE, Oncology, PARP inhibitor, Prostate cancer, UK 0 Comment

NHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they

NICE says no to AZ’s Lynparza for prostate cancer

https://pharmaphorum.com/news/nice-says-no-to-azs-lynparza-for-prostate-cancer/

News/ News/ Oncology

Filing beckons as Lynparza hits the mark in adjuvant breast cancer

Phil Taylor adjuvant, AstraZeneca, breast cancer, Lynparza, Oncology, PARP inhibitor 0 Comment

AstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer,

Filing beckons as Lynparza hits the mark in adjuvant breast cancer

https://pharmaphorum.com/news/filing-beckons-as-lynparza-hits-the-mark-in-adjuvant-breast-cancer/

News/ News/ Oncology

AZ’s cediranib falls short again in ovarian cancer combination

Richard Staines AstraZeneca, cancer, cediranib, Lynparza, Merck & Co, Oncology, ovarian cancer 0 Comment

AstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it

AZ’s cediranib falls short again in ovarian cancer combination

https://pharmaphorum.com/news/azs-cediranib-falls-short-again-in-ovarian-cancer-combination/

Trending

Lynparza

Login